D-0822-2018 Class II Terminated

Recalled by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) — Rockford, IL

FDA drug recall D-0822-2018 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on May 1, 2018 and is designated Class II. Reason for recall: GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination The recall status is terminated (terminated Mar 10, 2021). Affected quantity: 1,065 blister cards of 100 capsules each.

Recall details

Product Type
Drugs
Report Date
May 30, 2018
Initiation Date
May 1, 2018
Termination Date
Mar 10, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,065 blister cards of 100 capsules each

Product description

Loxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-902-20

Reason for recall

GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

Distribution pattern

Nationwide in the U.S.

Code information

Lot #: 3090454, Exp. 03/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0822-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0822-2018. Report a data issue: hello@regdatalab.com.